Market Place
Sourcing Support
FDA declines full approval for Intercept`s liver disease drug
13 Nov 2024 //
REUTERS
Intercept Provides Regulatory Update Regarding sNDA for OCALIVA
17 Oct 2024 //
GLOBENEWSWIRE
Intercept`s Ocaliva Faces Scrutiny At FDA Expert Meeting
17 Sep 2024 //
FIERCE PHARMA
Company Statement on FDA Advisory Committee Meeting
14 Sep 2024 //
GLOBENEWSWIRE
FDA Staff Questions Confirmatory Trial Data For Intercept`s Liver Drug
12 Sep 2024 //
ENDPTS
COBALT Trial Findings Published In American Journal Of Gastroenterology
06 Sep 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval to Genfit and Ipsen`s liver disease drug
11 Jun 2024 //
REUTERS
Intercept: OCA Effect On Liver Biomarkers In PBC Patients At EASL 2024
04 Jun 2024 //
GLOBENEWSWIRE
Intercept To Present New Data At EASL Congress 2024
29 May 2024 //
GLOBENEWSWIRE
Intercept Shows OCA Effect On Liver Markers, Fibrosis In PBC
20 May 2024 //
GLOBENEWSWIRE
Intercept Shows OCA-Bezafibrate Combo Impact On ALP, Metabolic Outcomes
18 May 2024 //
GLOBENEWSWIRE
Intercept To Present PBC Data At DDW 2024
09 May 2024 //
GLOBENEWSWIRE
Intercept Announces FDA Acceptance of sNDA for Ocaliva
29 Feb 2024 //
GLOBENEWSWIRE
Intercept Announces Phase 2 Data Showing Significant Impact of OCA-Bezafibrate
13 Nov 2023 //
GLOBENEWSWIRE
Intercept Announces Findings from Long-term Extension of Landmark POISE Trial
10 Nov 2023 //
GLOBENEWSWIRE
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
08 Nov 2023 //
GLOBENEWSWIRE
Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period
26 Oct 2023 //
BUSINESSWIRE
Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences
11 Oct 2023 //
BUSINESSWIRE
Alfasigma to take over struggling Intercept
27 Sep 2023 //
FIERCE PHARMA
Intercept to Conduct Fireside Chats and Meetings at Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
26 Jul 2023 //
GLOBENEWSWIRE
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate
23 Jun 2023 //
GLOBENEWSWIRE
Intercept Announces Restructuring Focus on Rare & Serious Liver Diseases
23 Jun 2023 //
GLOBENEWSWIRE
Intercept restructures as NASH hopes dashed again by FDA
23 Jun 2023 //
FIERCE PHARMA
FDA rejects Intercept’s NASH drug, prompting a pivot
22 Jun 2023 //
STAT NEWS
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid
22 Jun 2023 //
GLOBENEWSWIRE
Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA
07 Jun 2023 //
GLOBENEWSWIRE
Intercept to Conduct Meetings with Investors at Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Intercept tumbles on concerns over prospects of fatty liver disease drug
22 May 2023 //
REUTERS
FDA panel votes against approval of Intercept liver drug, cites safety issues
20 May 2023 //
REUTERS
Intercept still has a long road ahead with Ocaliva in NASH
19 May 2023 //
FIERCE PHARMA
Intercept Pharmaceuticals Stock Trading Halted Today
19 May 2023 //
GLOBENEWSWIRE
Intercept`s NASH bid in jeopardy after bleak FDA review
18 May 2023 //
FIERCE PHARMA
Intercept Receives FDA Orphan Drug Designation for the Fixed-Dose Combination
16 May 2023 //
GLOBENEWSWIRE
Intercept Announces New Data to be Presented at (EASL) Congress 2023
27 Apr 2023 //
GLOBENEWSWIRE
Intercept Reports 1Q 2023 FYR and Provides Updatefor NASH
27 Apr 2023 //
GLOBENEWSWIRE
Intercept to Announce First Quarter 2023 Financial Results
13 Apr 2023 //
GLOBENEWSWIRE
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid
10 Mar 2023 //
GLOBENEWSWIRE
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors
09 Mar 2023 //
GLOBENEWSWIRE
Intercept Reports Fourth Quarter and Full Year 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
Intercept Pharmaceuticals to Participate in Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
Intercept to Announce Q4 and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
Madrigal’s NASH candidate tops Intercept rival in ICER study
17 Feb 2023 //
FIERCE PHARMA
Intercept Receives Consensus Rating of "Moderate Buy" from Brokerages
08 Feb 2023 //
MARKETBEAT
FDA Accepts Intercept`s NDA for OCA for Pre-Cirrhotic Liver Fibrosis
19 Jan 2023 //
GLOBENEWSWIRE
By summer solstice, we`ll know the fate of Intercept`s NASH drug
19 Jan 2023 //
ENDPTS
Eying first NASH approval, Intercept gets FDA decision date
19 Jan 2023 //
FIERCE PHARMA
Intercept to Present at J.P. Morgan 41st Annual Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study
04 Jan 2023 //
GLOBENEWSWIRE
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid
23 Dec 2022 //
GLOBENEWSWIRE
New Study Published in The American Journal Pathology Suggests Obeticholic Acid
08 Dec 2022 //
GLOBENEWSWIRE
Intercept Pharma to Participate in Piper 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787
07 Nov 2022 //
GLOBENEWSWIRE
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes,
06 Nov 2022 //
GLOBENEWSWIRE
Intercept Pharmaceuticals Reports 3Q 2022 FYR and Provides Business Update
01 Nov 2022 //
GLOBENEWSWIRE
Intercept Announces Data to be Presented in PBC, Liver Fibrosis
31 Oct 2022 //
GLOBENEWSWIRE
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
25 Oct 2022 //
GLOBENEWSWIRE
Intercept Strikes Out in Phase III NASH Trial
04 Oct 2022 //
BIOSPACE
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
30 Sep 2022 //
FIERCEPHARMA
